Area of research
Hematology · Genetics
Research interest
Research interests include Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Myeloproliferative Neoplasms: Diagnosis and Treatment, and Acute Lymphoblastic Leukemia research.
Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance
Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile
A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo
Therapy-related MDS dissected based on primary disease and treatment—a nationwide perspective
Prediction model for drug response of acute myeloid leukemia patients
Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform
Vaccination Using an Allogeneic Leukemia-Derived Dendritic Cell Vaccine, Maintains and Improves Frequencies of Circulating Antigen Presenting Dendritic Cells Correlating with Relapse Free and Overall Survival in AML Patients
Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications
Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes
Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy
Chromosomal Abnormalities and Prognosis in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts
Expression levels of long non-coding RNAs are prognostic for AML outcome
Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies
Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling
Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease
Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997–2013
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
An open-label phase I dose-finding study of APR-246 in hematological malignancies
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by<i>DNMT3A</i>mutational status and associated with predominant hypomethylation of HOX genes
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry
Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies